121个药品通用名通过商保创新药目录初步形式审查

Group 1 - The National Healthcare Security Administration (NHSA) announced that 534 drug generic names passed the preliminary formal review for the 2025 National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug Catalog, a significant increase compared to the previous year [1][2] - A total of 718 submissions were received for the basic medical insurance catalog, with 633 drug generic names involved, and 534 passed the preliminary review, indicating a notable rise from 249 in 2024 [1][2] - The introduction of a commercial insurance innovative drug catalog alongside the basic medical insurance catalog reflects an enhancement of the role of commercial insurance in the multi-tiered medical security system [3] Group 2 - The formal review process is designed to ensure that submitted drugs meet the necessary conditions and that the information provided is complete and accurate, which is crucial for subsequent evaluation and assessment stages [2] - The NHSA emphasized that passing the preliminary formal review only indicates eligibility for further processes and does not guarantee inclusion in the drug catalog [2][3] - Feedback received during the public notice period will be used to verify the information of the drugs and finalize the list of those that passed the formal review [3]